Lilly’s Arxxant To Be Co-Promoted With Alcon
This article was originally published in The Pink Sheet Daily
Executive Summary
An FDA decision on the potential first-in-class diabetic retinopathy treatment is expected next month.
You may also be interested in...
Fate Of Speedel’s Diabetic Nephropathy Drug May Be Clearer Mid-Year 2007
DSMB halts Phase III trial of SPP301 due to an imbalance of fluid retention in patients in the study arms.
Fate Of Speedel’s Diabetic Nephropathy Drug May Be Clearer Mid-Year 2007
DSMB halts Phase III trial of SPP301 due to an imbalance of fluid retention in patients in the study arms.
Arxxant’s Fate In Question After FDA Requests Additional Trial
Lilly may seek a development partner for the diabetic retinopathy treatment to collect the three additional years of efficacy data sought by FDA.